Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
109 hedge funds and large institutions have $554M invested in Revance Therapeutics, Inc. in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 50 increasing their positions, 22 reducing their positions, and 17 closing their positions.
127% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less capital invested
Capital invested by funds: $564M → $554M (-$9.79M)
4% less funds holding
Funds holding: 114 → 109 (-5)
13% less call options, than puts
Call options by funds: $1.41M | Put options by funds: $1.61M
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$6.37M |
| 2 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$2.4M |
| 3 |
BAMCO Inc
New York
|
+$2.36M |
| 4 |
JP Morgan Chase
New York
|
+$2.2M |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$1.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$14.4M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5.8M |
| 3 |
Renaissance Technologies
New York
|
-$5.56M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.57M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.22M |
RVNC Hedge Fund Activity: Q3 2019 in Review
109 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q3 2019, worth a combined $554M — down 1.7% from $564M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of RVNC and 12 opened new positions — a net loss of 5 holders — while 22 trimmed existing stakes and 50 added.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $6.37M. The largest seller was Bank of New York Mellon, cutting an estimated $14.4M.
- 109 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q3 2019, down from 114 in Q2 2019.
- Funds reported $554M of Revance Therapeutics, Inc. stock for Q3 2019, down 1.7% quarter-over-quarter.
- 12 funds opened new Revance Therapeutics, Inc. positions in Q3 2019 and 17 closed out, a net change of -5 holders.
- The largest Revance Therapeutics, Inc. buyer in Q3 2019 was ArrowMark Colorado Holdings, an estimated $6.37M added.
- The largest Revance Therapeutics, Inc. seller in Q3 2019 was Bank of New York Mellon, an estimated $14.4M sold.
Based on aggregated 13F filings for Q3 2019.